In: Biological Psychiatry, Vol. 72, No. 7, 01.10.2012, p. 526-527.
Research output: Contribution to journal › Comment/debate
TY - JOUR
T1 - A "taste" of what is to come
T2 - Reward sensitivity as a potential endophenotype for major depressive disorder
AU - Simmons, W. Kyle
AU - Drevets, Wayne C.
N1 - Funding Information: Dr. Simmons' research is supported by National Institute of Mental Health Grant K01MH096175-01 , the Oklahoma Center for the Advancement for Science and Technology ( OCAST HR10-141 ), National Alliance for Research on Schizophrenia and Depression Young Investigator Award , and the Oklahoma Tobacco Research Center . Dr. Drevets' research is supported by the Oklahoma Center for the Advancement for Science and Technology (OCAST HR10-172) and the Stanley Foundation. Dr. Drevets is listed as coinventor on a use-patent for the use of scopolamine in major depression that has been filed by the U.S. government (through the National Institute of Mental Health). Dr. Drevets has consulted for Johnson and Johnson Pharmaceuticals, Inc., Eisai, Inc., and Myriad, Inc. and anticipates future compensation from Johnson & Johnson Pharmaceuticals.
PY - 2012/10/1
Y1 - 2012/10/1
UR - http://www.scopus.com/inward/record.url?scp=84866023874&partnerID=8YFLogxK
U2 - 10.1016/j.biopsych.2012.07.023
DO - 10.1016/j.biopsych.2012.07.023
M3 - Comment/debate
C2 - 22959120
AN - SCOPUS:84866023874
SN - 0006-3223
VL - 72
SP - 526
EP - 527
JO - Biological Psychiatry
JF - Biological Psychiatry
IS - 7